EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

PPAR Agonists for the Prevention and Treatment of Lung Cancer

Sowmya P Lakshmi iD, Aravind T Reddy iD, Asoka Banno, Raju C Reddy iD

PPAR Research · 2017 · 2017 · 1-8

DOI: 10.1155/2017/8252796 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift PPAR Research, 2017. Verfasst von Sowmya P Lakshmi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213,…. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NHLBI NIH HHS, U.S. Department of Veterans Affairs.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung cancer is the most common and most fatal of all malignancies worldwide. Furthermore, with more than half of all lung cancer patients presenting with distant metastases at the time of initial diagnosis, the overall prognosis for the disease is poor. There is thus a desperate need for new prevention and treatment strategies. Recently, a family of nuclear hormone receptors, the peroxisome proliferator-activated receptors (PPARs), has attracted significant attention for its role in various malignancies including lung cancer. Three PPARs, PPAR α , PPAR β / δ , and PPAR γ , display distinct biological activities and varied influences on lung cancer biology. PPAR α activation generally inhibits tumorigenesis through its antiangiogenic and anti-inflammatory effects. Activated PPAR γ is also antitumorigenic and antimetastatic, regulating several functions of cancer cells and controlling the tumor microenvironment. Unlike PPAR α and PPAR γ , whether PPAR β / δ activation is anti- or protumorigenic or even inconsequential currently remains an open question that requires additional investigation. This review of current literature emphasizes the multifaceted effects of PPAR agonists in lung cancer and discusses how they may be applied as novel therapeutic strategies for the disease.

Autor:innen und Institutionen

  • Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA; Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA 15…
  • Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.

ORCID-Profile: Sowmya P Lakshmi, Aravind T Reddy, Raju C Reddy

Förderung

  • NIAID NIH HHS
  • NHLBI NIH HHS
  • U.S. Department of Veterans Affairs
  • National Institutes of Health

Zitieren

APA

Lakshmi, S. P., Reddy, A. T., Banno, A., & Reddy, R. C. (2017). PPAR Agonists for the Prevention and Treatment of Lung Cancer. PPAR Research, 2017, 1-8. https://doi.org/10.1155/2017/8252796

Vancouver

Lakshmi SP, Reddy AT, Banno A, Reddy RC. PPAR Agonists for the Prevention and Treatment of Lung Cancer. PPAR Research. 2017;2017:1-8. doi:10.1155/2017/8252796

BibTeX
@article{Lakshmi2017,
  author = {Lakshmi, Sowmya P and Reddy, Aravind T and Banno, Asoka and Reddy, Raju C},
  title = {PPAR Agonists for the Prevention and Treatment of Lung Cancer},
  journal = {PPAR Research},
  year = {2017},
  volume = {2017},
  pages = {1--8},
  doi = {10.1155/2017/8252796}
}
Kostenlos starten →